- Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial
10:00 AM - 12:00 PM
Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE
10:00 AM - 12:00 PM
Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- The SGLT2 Inhibitor Canagliflozin Reduces the Plasma Markers TNFR-1, TNFR-2, and KIM-1 in the CANVAS Trial
10:00 AM - 12:00 PM
The SGLT2 Inhibitor Canagliflozin Reduces the Plasma Markers TNFR-1, TNFR-2, and KIM-1 in the CANVAS Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Canagliflozin Treatment Reduces Formation and Increases Degradation of Collagen Type III in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
10:00 AM - 12:00 PM
Canagliflozin Treatment Reduces Formation and Increases Degradation of Collagen Type III in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial
10:00 AM - 12:00 PM
Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial
10:00 AM - 12:00 PM
Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes
10:00 AM - 12:00 PM
Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program
10:00 AM - 12:00 PM
Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Kidney Effects of Empagliflozin in People with Type 1 Diabetes
10:00 AM - 12:00 PM
Kidney Effects of Empagliflozin in People with Type 1 Diabetes
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Empagliflozin Is Associated with Increased Plasma Lipid Metabolites in Type 1 Diabetes
10:00 AM - 12:00 PM
Empagliflozin Is Associated with Increased Plasma Lipid Metabolites in Type 1 Diabetes
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analysis from DECLARE-TIMI 58 Trial
10:00 AM - 12:00 PM
Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analysis from DECLARE-TIMI 58 Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Comparative Effectiveness of SGLT2 Inhibitors, GLP1 Receptor Agonists, DPP4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Healthcare Databases
10:00 AM - 12:00 PM
Comparative Effectiveness of SGLT2 Inhibitors, GLP1 Receptor Agonists, DPP4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Healthcare Databases
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Renal Outcomes and All-Cause Death Associated with SGLT-2 Inhibitor vs. Other Glucose-Lowering Drugs (CVD-REAL 3 Korea)
10:00 AM - 12:00 PM
Renal Outcomes and All-Cause Death Associated with SGLT-2 Inhibitor vs. Other Glucose-Lowering Drugs (CVD-REAL 3 Korea)
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Cardiovascular Outcomes with SGLT-2 Inhibitors vs. GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and CKD: A Systematic Review and Network Meta-Analysis
10:00 AM - 12:00 PM
Cardiovascular Outcomes with SGLT-2 Inhibitors vs. GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and CKD: A Systematic Review and Network Meta-Analysis
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Comparative Effectiveness of SGLT2 Inhibitors vs. Other Antihyperglycemics on Risk of Kidney Outcomes: A Cohort Study
10:00 AM - 12:00 PM
Comparative Effectiveness of SGLT2 Inhibitors vs. Other Antihyperglycemics on Risk of Kidney Outcomes: A Cohort Study
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Correlation of Anti-Albuminuric Effect by SGLT2 Inhibitor with Tubulointerstitial Impairment
10:00 AM - 12:00 PM
Correlation of Anti-Albuminuric Effect by SGLT2 Inhibitor with Tubulointerstitial Impairment
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- SGLT2i Prescribing for Type 2 Diabetes and Comorbid Conditions Among 24 US Healthcare Organizations
10:00 AM - 12:00 PM
SGLT2i Prescribing for Type 2 Diabetes and Comorbid Conditions Among 24 US Healthcare Organizations
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial
10:00 AM - 12:00 PM
Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist, for Patients with Type 2 Diabetes Mellitus and CKD
10:00 AM - 12:00 PM
Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist, for Patients with Type 2 Diabetes Mellitus and CKD
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Dulaglutide Treatment in Patients with Type 2 Diabetes and Moderate-to-Severe CKD Improves Kidney Fibrosis Biomarker Levels
10:00 AM - 12:00 PM
Dulaglutide Treatment in Patients with Type 2 Diabetes and Moderate-to-Severe CKD Improves Kidney Fibrosis Biomarker Levels
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Once-Weekly Exenatide Effects on eGFR Slope and Urine Albumin-to-Creatinine Ratio (UACR) as a Function of Baseline UACR: An EXSCEL Post Hoc Analysis
10:00 AM - 12:00 PM
Once-Weekly Exenatide Effects on eGFR Slope and Urine Albumin-to-Creatinine Ratio (UACR) as a Function of Baseline UACR: An EXSCEL Post Hoc Analysis
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs
10:00 AM - 12:00 PM
Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials
10:00 AM - 12:00 PM
Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Impacts of Glucagon-Like Peptide 1 Analogues and Sodium Glucose Cotransporter 2 Inhibitor on Type 2 Diabetes Patients with Renal Impairment
10:00 AM - 12:00 PM
Impacts of Glucagon-Like Peptide 1 Analogues and Sodium Glucose Cotransporter 2 Inhibitor on Type 2 Diabetes Patients with Renal Impairment
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- AKI Associated with Semaglutide
10:00 AM - 12:00 PM
AKI Associated with Semaglutide
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Association of Atrasentan Plasma Exposure with Variability in Responses in Proxies of Kidney Protection and Fluid Retention: A Post Hoc Analysis of the SONAR Trial
10:00 AM - 12:00 PM
Association of Atrasentan Plasma Exposure with Variability in Responses in Proxies of Kidney Protection and Fluid Retention: A Post Hoc Analysis of the SONAR Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effect of Oral Supplementation with Curcumin in Diabetic Subjects with Proteinuric Kidney Disease: A Randomized Controlled Trial
10:00 AM - 12:00 PM
Effect of Oral Supplementation with Curcumin in Diabetic Subjects with Proteinuric Kidney Disease: A Randomized Controlled Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effect of Praliciguat, a Once-Daily, Oral Soluble Guanylate Cyclase Stimulator, on Albuminuria in Patients with Diabetic Kidney Disease: A Randomized, Double-Blind, Phase 2 Trial
10:00 AM - 12:00 PM
Effect of Praliciguat, a Once-Daily, Oral Soluble Guanylate Cyclase Stimulator, on Albuminuria in Patients with Diabetic Kidney Disease: A Randomized, Double-Blind, Phase 2 Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Preexisting CKD Increases Risk of Metformin Monotherapy Failure in US Veterans with Type 2 Diabetes
10:00 AM - 12:00 PM
Preexisting CKD Increases Risk of Metformin Monotherapy Failure in US Veterans with Type 2 Diabetes
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Utilization of Glucose-Lowering Medications Among US Medicare Beneficiaries with CKD Between 2007 and 2016
10:00 AM - 12:00 PM
Utilization of Glucose-Lowering Medications Among US Medicare Beneficiaries with CKD Between 2007 and 2016
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Role of Roxadustat in Improving Erythropoiesis-Stimulating Agent (ESA)-Resistant Anemia in Patients on Maintenance Hemodialysis
10:00 AM - 12:00 PM
Role of Roxadustat in Improving Erythropoiesis-Stimulating Agent (ESA)-Resistant Anemia in Patients on Maintenance Hemodialysis
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Efficacy and Safety of Roxadustat in Patients with Dialysis-Dependent CKD, Anemia, and Diabetes Mellitus
10:00 AM - 12:00 PM
Efficacy and Safety of Roxadustat in Patients with Dialysis-Dependent CKD, Anemia, and Diabetes Mellitus
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Efficacy and Safety of Roxadustat in Patients with Non-Dialysis-Dependent CKD, Anemia, and Diabetes Mellitus
10:00 AM - 12:00 PM
Efficacy and Safety of Roxadustat in Patients with Non-Dialysis-Dependent CKD, Anemia, and Diabetes Mellitus
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effects of Veverimer on Serum Bicarbonate and Physical Function in Patients with Diabetes and CKD: Subgroup Analysis from a Randomized Trial
10:00 AM - 12:00 PM
Effects of Veverimer on Serum Bicarbonate and Physical Function in Patients with Diabetes and CKD: Subgroup Analysis from a Randomized Trial
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
